Şunu aradınız:: mds (İsveççe - İngilizce)

mds
mds

mds nordion
• mds nordion

mds/ mpd och gist
(starting dose 400 mg) hes/ cel (at dose 400 mg)

mds france (fr)
mds france (f)

dosering vid mds/mpd
posology for mds/mpd

myelodysplastiskt syndrom (mds).
romiplostim may induce the progression of existing haematological malignancies and myelodysplastic syndrome (mds).

kliniska studier vid mds/mpd
clinical studies in mds/mpd

om du behandlas för mds/mpd:
if you are being treated for mds/mpd:

dosering vid mds/mpd hos vuxna
posology for mds/mpd in adult patients

kml i kronisk fas, mds/mpd och gist
chronic phase cml, mds/mpd and gist

historik för aplastisk anemi eller mds (%)
history of aplastic anemia or mds (%)

progression av befintligt myelodysplastiskt syndrom (mds)
progression of existing myelodysplastic syndromes (mds)

myelodysplastiska/myeloproliferativa sjukdomar (mds/mpd).
myelodysplastic/myeloproliferative diseases (mds/mpd).

fallen var typiska för sekundärt mds/cancerbehandlingsrelaterad aml.
the cases were typical of secondary mds/cancer therapy-related aml.

behandlingen med filgrastim bör avbrytas om mds eller leukemi uppkommer.
if patients with scn develop abnormal cytogenetics, the risks and benefits of continuing filgrastim should be carefully weighed; filgrastim should be discontinued if mds or leukaemia occur.

ytterligare 24 patienter med mds/mpd rapporterades i 13 publikationer.
in addition a further 24 patients with mds/mpd were reported in 13 publications.

8 scn predisponerar dessa patienter för onormal cytogenetik, mds eller leukemi.
it is currently unclear whether long-term treatment of patients with scn will predispose patients to cytogenetic abnormalities, mds or leukaemic transformation.

mds och leukemier är naturliga komplikationer av sjukdomen och sambandet med filgrastimbehandling är osäkert.
mds and leukaemias are natural complications of the disease and are of uncertain relation to filgrastim therapy.

16 progression av befintliga hematopoetiska maligniteter eller myelodysplastiskt syndrom (mds)
16 progression of existing haematopoietic malignancies or myelodysplastic syndromes (mds)

beskrivning av risken för progression till aml för mds-patienter inklusive incidensfrekvenser från kliniska prövningar
description of the risk of progression to aml in mds patients including incidence rates from clinical trials